Welcome to our dedicated page for Ardent Health SEC filings (Ticker: ARDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ardent Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ardent Health's regulatory disclosures and financial reporting.
Ardent Health, Inc. (ARDT) is the issuer for a planned resale of its common stock under Rule 144 by Martin Bonick, identified as a former officer and director. The notice covers 35,930 shares of common stock to be sold through Fidelity Brokerage Services LLC, with a stated aggregate market value of $398,030.92 and listing on the NYSE. The shares to be sold relate to restricted stock vesting on 06/02/2026, received from the issuer as compensation.
The filing also lists sales by Martin Bonick during the past three months: three transactions of 35,930 shares of Ardent Health common stock on 08/18/2026, 08/20/2026, and 08/25/2026, with reported aggregate sale prices of $393,481.70, $377,363.99, and $401,355.23, respectively. Fidelity Brokerage Services LLC signs the notice as attorney-in-fact for Martin Bonick.
Ardent Health, Inc. (ARDT) is the issuer for which former officer and director Martin Bonick has filed a notice of proposed sales of common stock under Rule 144. The shares are held in an account at Fidelity Brokerage Services LLC and are listed on the NYSE.
The notice covers up to 35,930 shares of common stock with an aggregate market value of $401,355.23 and a CUSIP-identifying number of 141045907, with a Rule 144 filing date of 08/25/2026. It also discloses that 7,088 shares and 28,842 shares of restricted stock are scheduled to vest on 04/01/2026 and 06/02/2026, respectively, as compensation from the issuer.
In the prior three months, Bonick sold 35,930 shares of ARDT common stock on 08/18/2026 for proceeds of $393,481.70 and another 35,930 shares on 08/20/2026 for proceeds of $377,363.99, as reported in this notice.
Ardent Health, Inc. (ARDT) is the issuer for a Rule 144 notice covering planned sales of common stock held for the account of former officer and director Martin Bonick. The filing lists up to 35,930 shares of common stock, with an aggregate market value of $377,363.99, proposed for sale on 08/20/2026 through Fidelity Brokerage Services LLC on the NYSE. It also notes that the shares to be sold include restricted stock vesting events of 8,994 shares on 03/31/2026 and 26,936 shares on 04/01/2026, received from the issuer as compensation, and discloses a prior sale of 35,930 shares on 08/18/2026 for $393,481.70.
Ardent Health, Inc. (ARDT) is the issuer for a planned resale of common stock under Rule 144 by former officer and director Martin Bonick. The shares are held at Fidelity Brokerage Services LLC. The notice lists a proposed sale on the NYSE on 08/18/2026.
The securities to be sold relate to restricted stock vesting awards from the issuer, including 19,990 shares vesting on 03/31/2025 and 15,940 shares vesting on 03/31/2026, both described as compensation. Fidelity signed the notice as attorney-in-fact for Bonick.
Ardent Health, Inc. reported softer profitability for the quarter ended June 30, 2026. Total revenue was $1.62 billion, down modestly from $1.65 billion a year earlier, but net income attributable to Ardent declined to $16.9 million from $72.9 million, and diluted EPS fell to $0.12 from $0.52.
Results were pressured by a lower contribution from Medicaid supplemental payment programs in the quarter, higher professional fees, self‑insured liability costs and increased general and administrative expenses, including severance and CEO transition costs. For the first six months, revenue rose to $3.22 billion, yet net income attributable to Ardent decreased to $56.7 million. Operating cash flow strengthened to $136.5 million, cash and cash equivalents increased to $724.5 million, and total debt stayed around $1.10 billion, while interest rate swaps moved from a larger net liability to a smaller one, improving other comprehensive income. The company continues to derive most revenue from Texas, Oklahoma and New Mexico, with a payer mix led by Medicare and other managed care.
Ardent Health reported second quarter 2026 revenue of $1.62 billion, down 1.4% year-over-year, as net patient service revenue per adjusted admission fell 3.9% after a prior-year benefit from the New Mexico state directed payment program. Net income attributable to Ardent was $17 million or $0.12 per diluted share, compared with $73 million or $0.52, and Adjusted EBITDA declined to $115 million, a 32.3% decrease. Adjusted admissions grew 2.5% while total surgeries fell 2.9%.
Operating cash flow strengthened to $197 million, up 67% from $117 million, contributing to cash of $724 million, total debt of $1.1 billion, a net leverage ratio of 0.8x and lease-adjusted net leverage of 2.6x as of June 30, 2026. Available liquidity was $992 million, and the company repurchased 1.4 million shares for $13 million, with $34 million remaining under its authorization.
For full-year 2026, Ardent reaffirmed total revenue guidance of $6.4–$6.7 billion and Adjusted EBITDA of $485–$535 million, while lowering net income attributable guidance to $110–$163 million and diluted EPS guidance to $0.78–$1.15. Targets for adjusted admissions growth of 1.5–2.5% and capital expenditures of $225–$265 million were maintained.
Caspers Dave reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. reported that CEO and President Dave Caspers received an equity grant of 103,653 shares of Common Stock in the form of restricted stock units. These units vest in three substantially equal installments on each anniversary of July 1, 2026, as long as he remains with the company through each vesting date.
Following this award, Caspers directly holds 174,930 shares of Ardent Health common stock. The grant is compensation-related and was not an open-market purchase, as it carried a grant price of $0.00 per share.
Ardent Health, Inc. filed an update on leadership changes involving former President and CEO Martin J. Bonick. The company notes that Bonick’s previously announced departure on June 2, 2026 is now governed by a formal Separation Agreement and General Release dated June 26, 2026, effective as of the departure date.
Under this agreement, Bonick will receive severance benefits consistent with a termination by the company without “Cause,” as described in Ardent Health’s April 8, 2026 definitive proxy statement. The vesting or forfeiture of his time-based and performance-based restricted stock units and restricted stock will follow the existing incentive plan and award agreements. Bonick is also bound by non-competition and non-solicitation covenants for twelve months after the Effective Date. The full agreement is filed as Exhibit 10.1.
Ardent Health, Inc. director Robert DeMichiei reported an open-market purchase of Common Stock. He bought 11,260 shares at a weighted average price of $8.73 per share, increasing his direct holdings to 35,564 shares. The trade was executed through multiple transactions on June 5, 2026 at prices between $8.60 and $8.78.
Ardent Health, Inc. Chief Financial Officer Alfred Lumsdaine made an open-market purchase of 10,000 shares of Common Stock at $8.81 per share. After this transaction, he directly owns 329,183 shares, increasing his personal stake in the company.